

# **Does resting energy expenditure differ between women with and without polycystic ovary syndrome (PCOS): a systematic review and meta-analysis**

Richard Kirwan  
Georgia Kohlhoff

Leigh Peele  
Hannah Cabré  
James Steele

Greg Nuckols  
Alyssa Olenick

Invalid Date

Background: Polycystic ovary syndrome is the most common endocrine condition affecting women of reproductive age. Overweight and obesity in women with PCOS is commonly deemed a result of a lower basal metabolic rate (BMR), which has influenced lifestyle-based interventions in this group. Evidence supporting this reduced, however, is not consistent. Objectives: To systematically search and meta-analyse the existing literature to determine if resting energy expenditure differs between women with and without polycystic ovary syndrome (PCOS). Design: A systematic search was conducted using PubMed, Medline and Web of Science databases from January 1990 to January 2025. Studies that assessed resting energy expenditure in women with and without PCOS were included. Results: 18 studies were identified. Study populations ranged from X to X participants, with mean ages ranging from X to X years. Conclusions: TO ADD

## **Introduction**

Polycystic ovary syndrome (PCOS) affects approximately 10% of women of reproductive age worldwide, making it the most common endocrine disorder affecting this population (Salari et al., 2024). Due to a number of factors including hyperandrogenism and alterations in insulin resistance, PCOS is believed to contribute to an increased risk of diabetes, metabolic syndrome and cardiovascular disease (Glintborg et al., 2018, 2022, 2024; Lim et al., 2019; Persson et al., 2021), along with being a leading cause of anovulatory infertility in women (Joham et al., 2015). Furthermore, epidemiological data consistently demonstrates that women with PCOS

are significantly more likely to suffer from overweight or obesity, compared to the general female population, with estimates ranging from 38% to 88% of PCOS patients falling into these BMI categories (Barber, 2022; Barber & Franks, 2021).

The elevated incidence of overweight and obesity in PCOS is likely multifactorial with proposed mechanisms including blunted postprandial appetite hormone responses leading to reduced satiety and increased food cravings (Hirschberg et al., 2004; Moran et al., 2004; Stefanaki et al., 2024) and a reduced basal metabolic rate (BMR) (Georgopoulos et al., 2009). Indeed, the relevance of this reduced BMR, has become widely accepted amongst the scientific and medical community, with the original publication which reported this from Georgopoulos et al. (2009) having 109 citations according to Google Scholar metrics, as of writing (Add date and link!!!!). Furthermore, this publication has been widely disseminated amongst the lay community interested in PCOS, particularly in relation to lifestyle interventions, featuring in the top seven Google search results as of writing. However, despite the wide acceptance of this reported reduced BMR in PCOS, multiple other publications have found no such difference between women with and without PCOS (Graff et al., 2017; Larsson et al., 2016; Segal & Dunaif, 1990).

The consequences of this wide acceptance of a reduced BMR in women with PCOS should not be underestimated, particularly in light of the aforementioned incidence of overweight and obesity in this population. It has been well documented that women with PCOS suffer with anxiety, depression and a lower quality of life (QOL) as a result of negative body image due to, amongst other reasons, body weight concerns (Davitadze et al., 2023; Geller et al., 2025; Himelein & Thatcher, 2006; Hofmann et al., 2025). Consequently, women with PCOS have been observed to engage in more frequent weight-loss attempts than those without (Pesonen et al., 2023). Furthermore, intentional weight-loss is recognised as efficacious for improving the symptoms of PCOS (Alenezi et al., 2024; Holte et al., 1995) and, as such, is often recommended (Teede et al., 2023). However, while weight-loss is frequently pursued for body image and/or health-related reasons, women with PCOS may be discouraged from doing so due to the commonly held belief of lower BMR making weight loss attempts more difficult.

Therefore, to determine if there is indeed a difference in resting energy expenditure (REE) between women with and without PCOS, we completed a systematic review and meta-analysis of studies reporting REE in these populations.

## Methods

This systematic review and meta-analysis was pre-registered on PROSPERO ([CRD42024601434](https://www.crd42024601434)) initially on the 3<sup>rd</sup> of December 2024 and performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines (Liberati et al., 2009). The primary aim of this review was to examine the descriptive question “Does resting energy expenditure (REE) differ between women with and without polycystic ovary syndrome (PCOS)?”.

## Search Strategy

PubMed, Web of Science, and MEDLINE databases were searched using the following Boolean search string: ((“Basal Metabolic Rate”[MeSH] OR “Energy Metabolism”[MeSH] OR “Resting Metabolic Rate” OR RMR OR “Resting Energy Expenditure” OR REE OR “Basal Metabolic Rate” OR BMR OR “resting energy” OR “basal energy expenditure”) AND (“Polycystic Ovary Syndrome”[MeSH] OR “Polycystic Ovary Syndrome” OR PCOS OR “Polycystic Ovarian Disease” OR “Stein-Leventhal Syndrome”)). Searches were limited to publications up until May 2025 when the search was completed, limited to English language articles, and Rayyan was used to manage the search and screening process. Two reviewers (RK and GK) independently screened all titles and abstracts against the predefined inclusion and exclusion criteria. Articles deemed potentially eligible by either reviewer were retrieved in full text. Full texts were then independently assessed by RK and LP to determine final eligibility. Any disagreements at either stage were resolved through discussion, and when consensus could not be reached, a third reviewer acted as an adjudicator.

## Eligibility Criteria

The condition being studied was PCOS and we included observational cross-sectional design studies, in addition to studies of intervention where REE was reported for the population (and if included, the comparator) condition of interest. Following the PICO framework our eligibility criteria were as follows:

- Population
  - Inclusion criteria:
    - \* Women
    - \* 18-65 y
    - \* With or without insulin resistance (IS)
  - Exclusion criteria: -Studies using invalid or non-standard methods for measuring REE (e.g., predicted REE from body composition)
- Intervention(s) or exposure(s)
  - Otherwise healthy women with PCOS
- Comparator(s) or control(s)
  - Otherwise healthy control women without PCOS
- Outcome
- Resting energy expenditure (REE) measured via multiple methods including direct/indirect calorimetry, doubly labelled water.

Studies using invalid or non-standard methods for measuring BMR (e.g., predicted BMR from body composition) were excluded.

## Data extraction (selection and coding)

Bibliometric data including authors, journal, and title of article were extracted. Descriptive statistics for age, body mass, fat mass, fat free mass, height, BMI, race, physical activity levels, country of investigation, information regarding glucose/insulin regulation and insulin resistance status (where available) were extracted for each arm within each study in addition to sample size. Descriptive characteristics were then tabulated across studies for reporting.

The method of measuring REE was extracted and the units of measurement for which REE was reported. For each arm, and observation time point if multiple observations reported (e.g., before and after an intervention), depending on what was reported by the authors we extracted the means, medians, standard deviations, standard errors, lower and upper range values, and interquartile range for the unadjusted and/or body mass adjusted and/or fat free mass adjusted REE values. Where REE values adjusted for body mass and/or fat free mass were reported we used the reported body mass and/or fat free mass mean values for that arm to convert them to unadjusted REE values (i.e., multiplied them by body mass and/or fat free mass mean values). Where means and/or standard deviations were missing the latter were either calculated from standard errors and sample size, or all both were estimated from lower and upper range, interquartile range, median, and sample size depending on the information available using the methods of Wan et al. (2014). All REE values were converted to kcal/day.

## Statistical Analysis

Statistical analysis of the data extracted was performed in R, (v 4.3.3; R Core Team, <https://www.r-project.org/>) and RStudio (v 2023.06.1; Posit, <https://posit.co/>). All code utilised for data preparation, transformations, analyses, plotting, and reporting are available in the corresponding GitHub repository [https://github.com/jamessteelei/pcos\\_ree\\_meta](https://github.com/jamessteelei/pcos_ree_meta). We cite all software and packages used in the analysis pipeline using the `grateful` package (Rodriguez-Sanchez et al., 2023) which can be seen here: [https://github.com/jamessteelei/pcos\\_ree\\_meta/blob/main/grateful-report.pdf](https://github.com/jamessteelei/pcos_ree_meta/blob/main/grateful-report.pdf). The statistical analysis plan was linked in our pre-registration (PROSPERO: [CRD42024601434](https://doi.org/10.1186/1745-6215-42024601434)) and available at the accompanying github repository. Any deviations from the pre-registration are noted below.

Given our research question our analysis was aimed at parameter estimation (Cumming, 2014) within a Bayesian meta-analytic framework (Kruschke & Liddell, 2018). For all analyses model parameter estimates and their precision, along with conclusions based upon them, are interpreted continuously and probabilistically, considering data quality, plausibility of effect, and previous literature, all within the context of each model. The `renv` package (Ushey et al., 2023) was used for package version reproducibility and a function based analysis pipeline using the `targets` package (Landau et al., 2023) was employed (the analysis pipeline can be viewed by downloading the R Project and running the function `targets::tar_visnetwork()`). Effect sizes and their variances were all calculated using the `metafor` packages `escalc()` function (Viechtbauer, 2023). The main package `brms` (Bürkner et al., 2023) was used in fitting all the

Bayesian meta-analysis models. Prior and posterior draws were taken using `marginalEffects` (Arel-Bundock et al., 2023) and `tidybayes` (Kay & Mastny, 2023) packages. All visualisations are created using `ggplot2` (Wickham et al., 2023), `tidybayes`, and the `patchwork` (Pedersen, 2023) packages.

## **Main Pre-registered Models**

We adopted an arm-based multiple condition comparison (i.e., network) type model given that the studies included had arms of women with PCOS both with, and without, a non-PCOS control arm (Hong et al., 2016), and also in some cases multiple observations of REE in the different arms included in the study. In typical contrast-based meta-analyses data is limited to the effect sizes for paired contrasts between arms and thus studies that include both arms (i.e., relative effects between non-PCOS control vs PCOS arms); however, in arm-based analyses the data are the absolute effects within each arm and information is borrowed across studies to enable both within condition absolute, and between condition relative contrasts to be estimated. From this model we focus on reporting the global grand mean estimate for the fixed between condition relative contrast for non-PCOS control vs PCOS arms as our primary estimand of interest (i.e.,  $\beta_1$  in both mean and standard deviation models). We examined both raw mean REE (i.e., the absolute mean REE in kcals per day for each arm) in addition to the between person standard deviation in REE (i.e., the absolute standard deviation in REE in kcals per day for each arm). Both models were multilevel in that they included nested random intercepts for both study, and arm within study, and in addition and in deviation from our pre-registration we also included lab as a random intercept as in some cases we had multiple studies from the same lab or research group included. Lastly, the inclusion of a random intercept for each effect size was also accidentally omitted from our pre-registration and so this is also included in the model.

### **Mean REE Model**

The main model for mean REE with `cond` representing the condition (either control or PCOS)

was as follows:

$$\begin{aligned}
\hat{\theta}_{ijkl} &\sim \mathcal{N}(\mu_{ijkl}, \sigma_{ijkl}^2) \\
\mu_{ijkl} &= \beta_0 + \beta_1 \text{cond}[ijkl] + \alpha_{0,\text{lab}[i]} + \alpha_{1,\text{lab}[i]} \text{cond} + \alpha_{0,\text{study}[j]} + \alpha_{1,\text{study}[j]} \text{cond} + \alpha_{0,\text{arm}[k]} + \alpha_{0,\text{effect}[l]} \\
\begin{pmatrix} \alpha_{0,\text{lab}[i]} \\ \alpha_{1,\text{lab}[i]} \end{pmatrix} &\sim \mathcal{N}\left(\begin{pmatrix} 0 \\ 0 \end{pmatrix}, \Sigma_{\text{lab}}\right), \quad \Sigma_{\text{lab}} = \begin{pmatrix} \sigma_{0,\text{lab}}^2 & \rho_{\text{lab}} \sigma_{0,\text{lab}} \sigma_{1,\text{lab}} \\ \rho_{\text{lab}} \sigma_{0,\text{lab}} \sigma_{1,\text{lab}} & \sigma_{1,\text{lab}}^2 \end{pmatrix}, \text{ for lab } i = 1, \dots, I \\
\begin{pmatrix} \alpha_{0,\text{study}[j]} \\ \alpha_{1,\text{study}[j]} \end{pmatrix} &\sim \mathcal{N}\left(\begin{pmatrix} 0 \\ 0 \end{pmatrix}, \Sigma_{\text{study}}\right), \quad \Sigma_{\text{study}} = \begin{pmatrix} \sigma_{0,\text{study}}^2 & \rho_{\text{study}} \sigma_{0,\text{study}} \sigma_{1,\text{study}} \\ \rho_{\text{study}} \sigma_{0,\text{study}} \sigma_{1,\text{study}} & \sigma_{1,\text{study}}^2 \end{pmatrix}, \text{ for study } j = 1, \dots, J \\
\alpha_{0,\text{arm}[k]} &\sim \mathcal{N}(0, \sigma_{0,\text{arm}}^2), \text{ for arm } k = 1, \dots, K \\
\alpha_{0,\text{effect}[l]} &\sim \mathcal{N}(0, \sigma_{0,\text{effect}}^2), \text{ for effect } l = 1, \dots, L
\end{aligned}$$

where  $\hat{\theta}_{ijkl}$  is the  $l$ th mean REE estimate from the  $k$ th arm, for the  $j$ th study, conducted by the  $i$ th lab and  $\sigma_{ijkl}^2$  is the corresponding sampling error for that estimate. The random intercepts for the  $i$ th lab,  $j$ th study,  $k$ th arm, and  $l$ th mean REE estimate are  $\alpha_{0,\text{lab}[i]}$ ,  $\alpha_{0,\text{study}[j]}$ ,  $\alpha_{0,\text{arm}[k]}$ , and  $\alpha_{0,\text{effect}[l]}$  respectively each with standard deviation of  $\sigma_{0,\text{lab}[i]}^2$ ,  $\sigma_{0,\text{study}[j]}^2$ ,  $\sigma_{0,\text{arm}[k]}^2$ , and  $\sigma_{0,\text{effect}[l]}^2$ . The parameter  $\beta_0$  represents the fixed effect estimate of REE for control conditions and  $\beta_1$  the fixed effect estimate for the offset from this for the PCOS conditions (i.e., the difference between conditions). The estimated offset was allowed to vary across both labs and studies each reflected by  $\alpha_{1,\text{lab}[i]}$  and  $\alpha_{1,\text{study}[j]}$  respectively, and these effects were also modelled as correlated with the corresponding random intercepts with covariance  $\Sigma_{\text{lab}}$  and  $\Sigma_{\text{study}}$ , and  $\text{corr}_{\text{lab}}$  and  $\text{corr}_{\text{study}}$  correlation matrices.

The priors for this model were as follows:

$$\begin{aligned}
\beta_0 &\sim \text{Student-}t(3, 1441.81, 84.56) \\
\beta_1 &\sim \text{Student-}t(3, 0, 200) \\
\sigma_{0,\text{study}}^2 &\sim \text{Half-student-}t(3, 149.89, 82.91) \\
\sigma_{0,\text{lab}}^2, \sigma_{1,\text{lab}}^2, \sigma_{1,\text{study}}^2, \sigma_{0,\text{arm}}^2, \sigma_{0,\text{effect}}^2 &\sim \text{Half-student-}t(3, 0, 112.4) \\
\text{corr}_{\text{lab}} &\sim \text{LKJ}(1) \\
\text{corr}_{\text{study}} &\sim \text{LKJ}(1)
\end{aligned}$$

where the prior for  $\beta_0$ , which corresponded to the model intercept and mean REE in the control condition, was set based on meta-analysis of the mean REEs for women from two large studies of healthy people (Pavlidou et al., 2023; Velasquez, 2011) though set with a conservative degrees of freedom for the Student- $t$  distribution. The random intercept  $\sigma_{0,\text{study}}^2$  was set similarly to this. The prior for the fixed effect  $\beta_1$ , reflecting the difference between

control and PCOS conditions was set based on a wide range of possible values considering the minimum and maximum values of the ranges reported in the two studies noted (i.e.,  $2492 - 908 = 1584$ ). We then set a prior that permits values approximately across this range of values with the majority of it's mass centred around zero. The remaining random effects were set based on the default weakly regularising priors for `brms` and scaled to the expected response values using a half-student- $t$  distribution with 3 degrees of freedom and  $\mu = 0$ , and both correlation matrices  $\text{corr}_{lab}$  and  $\text{corr}_{study}$  were set with an `LKJcorr(1)` distribution.

## Standard Deviation of REE Model

The main model for the standard deviation of REE with `cond` representing the condition (either control or PCOS) was as follows:

$$\begin{aligned}
\log(\hat{\theta}_{ijkl}) &\sim \mathcal{N}(\mu_{ijkl}, \sigma_{ijkl}^2) \\
\mu_{ijkl} &= \beta_0 + \beta_1 \text{cond}_{[ijkl]} + \beta_2 \tilde{m}_{[ijkl]} + \alpha_{0,lab[i]} + \alpha_{1,lab[i]} \text{cond} + \alpha_{0,study[j]} + \alpha_{1,study[j]} \text{cond} + \alpha_{0,arm[k]} + \alpha_{0,effect[l]} \\
m &= \log(y_{i,\text{mean},[ijkl]}) \\
\tilde{m} &\sim \mathcal{N}(m, \sigma_{\log(y_{i,\text{mean},[ijkl]})}^2) \\
\begin{pmatrix} \alpha_{0,lab[i]} \\ \alpha_{1,lab[i]} \end{pmatrix} &\sim \mathcal{N}\left(\begin{pmatrix} 0 \\ 0 \end{pmatrix}, \Sigma_{lab}\right), \quad \Sigma_{lab} = \begin{pmatrix} \sigma_{0,lab}^2 & \rho_{lab} \sigma_{0,lab} \sigma_{1,lab} \\ \rho_{lab} \sigma_{0,lab} \sigma_{1,lab} & \sigma_{1,lab}^2 \end{pmatrix}, \text{ for lab } i = 1, \dots, I \\
\begin{pmatrix} \alpha_{0,study[j]} \\ \alpha_{1,study[j]} \end{pmatrix} &\sim \mathcal{N}\left(\begin{pmatrix} 0 \\ 0 \end{pmatrix}, \Sigma_{study}\right), \quad \Sigma_{study} = \begin{pmatrix} \sigma_{0,study}^2 & \rho_{study} \sigma_{0,study} \sigma_{1,study} \\ \rho_{study} \sigma_{0,study} \sigma_{1,study} & \sigma_{1,study}^2 \end{pmatrix}, \text{ for study } j = 1, \dots, J \\
\alpha_{0,arm[k]} &\sim \mathcal{N}(0, \sigma_{0,arm}^2), \text{ for arm } k = 1, \dots, K \\
\alpha_{0,effect[l]} &\sim \mathcal{N}(0, \sigma_{0,effect}^2), \text{ for effect } l = 1, \dots, L
\end{aligned}$$

where  $\log(\hat{\theta}_{ijkl})$  is the  $l$ th natural logarithm of the standard deviation of REE estimate from the  $k$ th arm, for the  $j$ th study, conducted by the  $i$ th lab and  $\sigma_{ijkl}^2$  is the corresponding sampling error for that estimate. The random intercepts for the  $i$ th lab,  $j$ th study,  $k$ th arm, and  $l$ th standard deviation of REE estimate are  $\alpha_{0,lab[i]}$ ,  $\alpha_{0,study[j]}$ ,  $\alpha_{0,arm[k]}$ , and  $\alpha_{0,effect[l]}$  respectively each with standard deviation of  $\sigma_{0,lab[i]}^2$ ,  $\sigma_{0,study[j]}^2$ ,  $\sigma_{0,arm[k]}^2$ , and  $\sigma_{0,effect[l]}^2$ . The parameter  $\beta_0$  represents the fixed effect estimate of standard deviation of REE for control conditions and  $\beta_1$  the fixed effect estimate for the offset from this for the PCOS conditions (i.e., the difference between conditions). The estimated offset was allowed to vary across both labs and studies each reflected by  $\alpha_{1,lab[i]}$  and  $\alpha_{1,study[j]}$  respectively, and these effects were also modelled as correlated with the corresponding random intercepts with covariance  $\Sigma_{lab}$  and  $\Sigma_{study}$ , and  $\text{corr}_{lab}$  and  $\text{corr}_{study}$  correlation matrices. Finally,  $\beta_2$  represents the fixed effect of the natural logarithm of the corresponding mean REE estimate  $\tilde{m}$  which is modelled

as estimated with measurement error i.e.,  $m$  represents the point estimate for the  $l$ th natural logarithm of the mean REE estimate from the  $k$ th arm, for the  $j$ th study, conducted by the  $i$ th lab and  $\sigma_{\log(y_{i,\text{mean},[ijkl]})}^2$  is the corresponding sampling error for that estimate.

The priors for this model were as follows:

$$\begin{aligned}
\beta_0 &\sim \text{Student-}t(3, 5.54, 0.80) \\
\beta_1 &\sim \text{Student-}t(3, 0, 5.3) \\
\beta_2 &\sim \text{Student-}t(3, 0, 2.5) \\
\text{mean}(\tilde{m}) &\sim \text{Half-student-}t(3, 7.28, 0.62) \\
\text{sd}(\tilde{m}) &\sim \text{Half-student-}t(3, 0, 5) \\
\sigma_{0,\text{study}}^2 &\sim \text{Half-student-}t(3, 1.08, 1.06) \\
\sigma_{0,\text{lab}}^2, \sigma_{1,\text{lab}}^2, \sigma_{1,\text{study}}^2, \sigma_{0,\text{arm}}^2, \sigma_{0,\text{effect}}^2 &\sim \text{Half-student-}t(3, 0, 2.5) \\
\text{corr}_{\text{lab}} &\sim \text{LKJ}(1) \\
\text{corr}_{\text{study}} &\sim \text{LKJ}(1)
\end{aligned}$$

where the prior for  $\beta_0$ , which corresponded to the model intercept and standard deviation of REE in the control condition, was again set based on meta-analysis of the standard deviation of REEs for women from two large studies of healthy people (Pavlidou et al., 2023; Velasquez, 2011) though set with a conservative degrees of freedom for the Student- $t$  distribution. The random intercept  $\sigma_{0,\text{study}}^2$  was set similarly to this. The prior for the fixed effect  $\beta_1$ , reflecting the difference between control and PCOS conditions was set based on a wide range of possible values. Given that in many cases of variables in the field there is an approximate relationship of  $\sim 1$  for the natural logarithm of the standard deviation conditioned upon the natural logarithm of the mean (Steele et al., 2023) we set this prior to reflect the range of differences on the on the log scale (i.e.,  $\log(1584)$ ). We then set a prior that permits values approximately across this range of values with the majority of it's mass centred around zero. The prior for the fixed effect  $\beta_2$ , reflecting the relationship between the natural logarithm of the mean REE with the natural logarithm of the standard deviation of REE, was set it to be weakly informative centred on zero with a wide scale to indicate uncertainty in this outcome specifically despite the typical relationship close to  $\sim 1$ . Priors for the measurement error of the natural logarithm of the mean REE estimate  $\tilde{m}$  were again based upon meta-analysis of the aforementioned studies, though measurement error has to be positive, as does the corresponding standard deviation of this error, so we set these to conservative wide half-student- $t$  distributions. The remaining random effects were set based on the default weakly regularising priors for **brms** and scaled to the expected response values using a half-student- $t$  distribution with 3 degrees of freedom and  $\mu = 0$ , and both correlation matrices  $\text{corr}_{\text{lab}}$  and  $\text{corr}_{\text{study}}$  were set with an LKJcorr(1) distribution.



## Post-processing of models

For both models we examined trace plots along with  $\hat{R}$  values to examine whether chains have converged, and posterior predictive checks for each model to understand the model implied distributions. From each model we took draws from the posterior distributions for the conditional absolute estimates for each condition (i.e., controls and PCOS) by study incorporating random effects, the global grand mean absolute estimates for each condition ignoring random effects, and the global grand mean between condition relative contrast for controls vs PCOS conditions ignoring random effects. The between condition relative contrast for controls vs PCOS conditions corresponded to  $\beta_1$  in each model and was our primary estimand of interest; for the mean REE model this corresponded to the absolute difference in mean REE, and for the standard deviation of REE model this corresponded to the natural logarithm of the ratio of standard deviations of REE which was exponentiated (note, all log standard deviation of REE model estimates were exponentiated back to the original scale to aid interpretability). We present the full probability density functions for posterior visually, and also to calculate mean and 95% quantile intervals (QI: i.e., ‘credible’ or ‘compatibility’ intervals) for each estimate providing the most probable value of the parameter in addition to the range from 2.5% to 97.5% percentiles given our priors and data.

## Sensitivity analysis using pairwise contrast based models

By way of sensitivity analysis we also conducted pairwise contrast based models where we limited the included effects to those extracted from studies including only a directly comparable control and PCOS arm at baseline. These models were both as follows:

$$\begin{aligned}\hat{\theta}_{ij} &\sim \mathcal{N}(\mu_{ij}, \sigma_{ij}^2) \\ \mu_{ij} &= \beta_0 + \alpha_{0,\text{lab}[i]} + \alpha_{0,\text{study}[j]} \\ \alpha_{0,\text{lab}[i]} &\sim \mathcal{N}(0, \sigma_{0,\text{lab}}^2), \text{ for lab } i = 1, \dots, I \\ \alpha_{0,\text{study}[j]} &\sim \mathcal{N}(0, \sigma_{0,\text{study}}^2), \text{ for study } j = 1, \dots, J\end{aligned}$$

where  $\hat{\theta}_{ijkl}$  is the pairwise effect size, either the mean difference in REE or the log coefficient of variation ratio (calculated as PCOS vs control), for the  $j$ th study, conducted by the  $i$ th lab and  $\sigma_{ijkl}^2$  is the corresponding sampling error for that effect size estimate. The random intercepts for the  $i$ th lab,  $j$ th study are  $\alpha_{0,\text{lab}[i]}$  and  $\alpha_{0,\text{study}[j]}$  respectively each with standard deviation of  $\sigma_{0,\text{lab}[i]}^2$ ,  $\sigma_{0,\text{study}[j]}^2$ . The parameter  $\beta_0$  represents the fixed effect estimate of the pairwise effect size i.e., the pooled estimate of the contrast between conditions. The priors for  $\beta_0$  in these models were set as default weakly regularising which is set on an intercept that results when internally centering all population-level predictors around zero to improve sampling efficiency and scaled to the expected response values using a student- $t$  distribution;

for the mean difference in REE this was student- $t(3, 5.5, 50.2)$  and for the log coefficient of variance ratio this was student- $t(3, -0.1, 2.5)$ . The random effects were set similarly scaled to the expected response values but using a half-student- $t$  distribution centred on zero. From these models we calculated the mean and 95% quantile intervals (i.e., ‘credible’ or ‘compatibility’ intervals) for the  $\beta_0$  (comparable to the  $\beta_1$  from the corresponding mean and standard deviation of REE arm-based models) for each effect size providing the most probable value of the parameter in addition to the range from 2.5% to 97.5% percentiles given our priors and data.

## Results

A total of 17 studies from 13 labs including 33 arms (Control arms = 9, PCOS arms = 15) and a total of 918 participants (Controls: minimum  $n = 9$ , median  $n = 29$ , maximum  $n = 54$ ; PCOS: minimum  $n = 5$ , median  $n = 28$ , maximum  $n = 266$ ). Descriptive characteristics of the arms and participants in these studies are reported in Table 1.

### Mean REE Model Results

The main model for mean REE resulted in a posterior distribution for the contrast between control and PCOS conditions with a mean point estimate of 37 kcal/day with a 95% quantile interval ranging from -39 kcal/day to 129 kcal/day suggesting there is a 95% probability that the true difference lies between these values given our priors and the data from included studies. The corresponding conditional estimates for the control condition and PCOS condition respectively were 1479 kcal/day [95%QI:1375 kcal/day to 1591 kcal/day] and 1516 kcal/day [95%QI:1409 kcal/day to 1625 kcal/day]. These results including the full visualisation of the posterior distribution, in addition to the conditional estimates by study, can be seen in Figure 1.

### Standard Deviation of REE Model Results

The main model for the between participant standard deviation of REE resulted in a posterior distribution for the contrast ratio between control and PCOS conditions with a mean point estimate of 1.05 with a 95% quantile interval ranging from 0.75 to 1.47 suggesting there is a 95% probability that the true ratio of standard deviations lies between these values given our priors and the data from included studies. The corresponding conditional estimates for the standard deviations of the control condition and PCOS condition respectively were 247 kcal/day [95%QI:182 kcal/day to 333 kcal/day] and 254 kcal/day [95%QI:188 kcal/day to 335 kcal/day]. These results including the full visualisation of the posterior distribution, in addition to the conditional estimates by study, can be seen in Figure 2.

## Mean Resting Energy Expenditure




Figure 1: Posterior distribution, mean point estimates, and 95% quantile intervals for conditional estimates by study, global grand mean estimates by condition, and the contrast between conditions for mean resting energy expenditure of control women without PCOS and women with PCOS.

## Standard Deviation of Resting Energy Expenditure




Figure 2: Posterior distribution, variance point estimates, and 95% quantile intervals for conditional estimates by study, global grand variance estimates by condition, and the contrast ratio between conditions for the standard deviation of resting energy expenditure of control women without PCOS and women with PCOS.

## Sensitivity Analysis with Pairwise Models

For mean REE the pairwise model resulted in qualitatively similar inferences suggesting little difference between control and PCOS conditions with mean point estimate of 16 kcal/day with a 95% quantile interval ranging from -36 kcal/day to 70 kcal/day. This was similar for the standard deviation of REE with the pairwise model resulting in a contrast ratio between control and PCOS conditions with a mean point estimate of 0.9 with a 95% quantile interval ranging from 0.6 to 1.35.

## References

- Alenezi, S. A., Elkmeshi, N., Alanazi, A., Alanazi, S. T., Khan, R., & Amer, S. (2024). The Impact of Diet-Induced Weight Loss on Inflammatory Status and Hyperandrogenism in Women with Polycystic Ovarian Syndrome (PCOS)-A Systematic Review and Meta-Analysis. *Journal of Clinical Medicine*, 13(16), 4934. <https://doi.org/10.3390/jcm13164934>
- Arel-Bundock, V., cre, cph, Diniz, M. A., Greifer, N., & Bacher, E. (2023). *Marginal effects: Predictions, Comparisons, Slopes, Marginal Means, and Hypothesis Tests*.
- Barber, T. M. (2022). Why are women with polycystic ovary syndrome obese? *British Medical Bulletin*, 143(1), 4–15. <https://doi.org/10.1093/bmb/ldac007>
- Barber, T. M., & Franks, S. (2021). Obesity and polycystic ovary syndrome. *Clinical Endocrinology*, 95(4), 531–541. <https://doi.org/10.1111/cen.14421>
- Bürkner, P.-C., Gabry, J., Weber, S., Johnson, A., Modrak, M., Badr, H. S., Weber, F., Ben-Shachar, M. S., Rabel, H., Mills, S. C., & Wild, S. (2023). *Brms: Bayesian Regression Models using 'Stan'*.
- Cumming, G. (2014). The New Statistics: Why and How. *Psychological Science*, 25(1), 7–29. <https://doi.org/10.1177/0956797613504966>
- Davitadze, M., Malhotra, K., Khalil, H., Hebbar, M., Tay, C. T., Mousa, A., PCOS SEva team, Teede, H., Brennan, L., Stener-Victorin, E., & Kempegowda, P. (2023). Body image concerns in women with polycystic ovary syndrome: A systematic review and meta-analysis. *European Journal of Endocrinology*, 189(2), R1–R9. <https://doi.org/10.1093/ejendo/lvad110>
- Geller, S., Levy, S., & Avitsur, R. (2025). Body image, illness perception, and psychological distress in women coping with polycystic ovary syndrome (PCOS). *Health Psychology Open*, 12, 20551029251327441. <https://doi.org/10.1177/20551029251327441>
- Georgopoulos, N. A., Saltamavros, A. D., Vervita, V., Karkoulas, K., Adonakis, G., Decavalas, G., Kourounis, G., Markou, K. B., & Kyriazopoulou, V. (2009). Basal metabolic rate is decreased in women with polycystic ovary syndrome and biochemical hyperandrogenemia and is associated with insulin resistance. *Fertility and Sterility*, 92(1), 250–255. <https://doi.org/10.1016/j.fertnstert.2008.04.067>

- Glintborg, D., Kolster, N. D., Ravn, P., & Andersen, M. S. (2022). Prospective Risk of Type 2 Diabetes in Normal Weight Women with Polycystic Ovary Syndrome. *Biomedicines*, 10(6), 1455. <https://doi.org/10.3390/biomedicines10061455>
- Glintborg, D., Ollila, M.-M., Møller, J.-J. K., Pesonen, P., Persson, S., Elenis, E., Rubin, K. H., Gissler, M., Andersen, M. S., Sundström-Poromaa, I., & Piltonen, T. (2024). Prospective risk of Type 2 diabetes in 99 892 Nordic women with polycystic ovary syndrome and 446 055 controls: National cohort study from Denmark, Finland, and Sweden. *Human Reproduction (Oxford, England)*, 39(8), 1823–1834. <https://doi.org/10.1093/humrep/deae124>
- Glintborg, D., Rubin, K. H., Nybo, M., Abrahamsen, B., & Andersen, M. (2018). Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. *Cardiovascular Diabetology*, 17(1), 37. <https://doi.org/10.1186/s12933-018-0680-5>
- Graff, S. K., Mario, F. M., Magalhães, J. A., Moraes, R. S., & Spritzer, P. M. (2017). Saturated Fat Intake Is Related to Heart Rate Variability in Women with Polycystic Ovary Syndrome. *Annals of Nutrition & Metabolism*, 71(3-4), 224–233. <https://doi.org/10.1159/000484325>
- Himelein, M. J., & Thatcher, S. S. (2006). Depression and body image among women with polycystic ovary syndrome. *Journal of Health Psychology*, 11(4), 613–625. <https://doi.org/10.1177/1359105306065021>
- Hirschberg, A. L., Naessén, S., Stridsberg, M., Byström, B., & Holtet, J. (2004). Impaired cholecystokinin secretion and disturbed appetite regulation in women with polycystic ovary syndrome. *Gynecological Endocrinology: The Official Journal of the International Society of Gynecological Endocrinology*, 19(2), 79–87. <https://doi.org/10.1080/09513590400002300>
- Hofmann, K., Decrinis, C., Bitterlich, N., Tropschuh, K., Stute, P., & Bachmann, A. (2025). Body image and mental health in women with polycystic ovary syndrome-a cross-sectional study. *Archives of Gynecology and Obstetrics*, 312(1), 177–190. <https://doi.org/10.1007/s00404-024-07913-4>
- Holte, J., Bergh, T., Berne, C., Wide, L., & Lithell, H. (1995). Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. *The Journal of Clinical Endocrinology and Metabolism*, 80(9), 2586–2593. <https://doi.org/10.1210/jcem.80.9.7673399>
- Hong, H., Chu, H., Zhang, J., & Carlin, B. P. (2016). A Bayesian missing data framework for generalized multiple outcome mixed treatment comparisons. *Research Synthesis Methods*, 7(1), 6–22. <https://doi.org/10.1002/jrsm.1153>
- Joham, A. E., Teede, H. J., Ranasinha, S., Zoungas, S., & Boyle, J. (2015). Prevalence of infertility and use of fertility treatment in women with polycystic ovary syndrome: Data from a large community-based cohort study. *Journal of Women's Health (2002)*, 24(4), 299–307. <https://doi.org/10.1089/jwh.2014.5000>
- Kay, M., & Mastny, T. (2023). *Tidybayes: Tidy Data and 'Geoms' for Bayesian Models*.
- Kruschke, J. K., & Liddell, T. M. (2018). The Bayesian New Statistics: Hypothesis testing, estimation, meta-analysis, and power analysis from a Bayesian perspective [Journal Article]. *Psychonomic Bulletin & Review*, 25, 178–206.
- Landau, W. M., Warkentin, M. T., Edmondson, M., Oliver, S., Mahr, T., & Company, E. L. and. (2023). *Targets: Dynamic Function-Oriented 'Make'-Like Declarative Pipelines*.
- Larsson, I., Hulthén, L., Landén, M., Pålsson, E., Janson, P., & Stener-Victorin, E. (2016).

- Dietary intake, resting energy expenditure, and eating behavior in women with and without polycystic ovary syndrome. *Clinical Nutrition (Edinburgh, Scotland)*, 35(1), 213–218. <https://doi.org/10.1016/j.clnu.2015.02.006>
- Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. *Journal of Clinical Epidemiology*, 62(10), e1–34. <https://doi.org/10.1016/j.jclinepi.2009.06.006>
- Lim, S. S., Kakoly, N. S., Tan, J. W. J., Fitzgerald, G., Bahri Khomami, M., Joham, A. E., Cooray, S. D., Misso, M. L., Norman, R. J., Harrison, C. L., Ranasinha, S., Teede, H. J., & Moran, L. J. (2019). Metabolic syndrome in polycystic ovary syndrome: A systematic review, meta-analysis and meta-regression. *Obesity Reviews: An Official Journal of the International Association for the Study of Obesity*, 20(2), 339–352. <https://doi.org/10.1111/obr.12762>
- Moran, L. J., Noakes, M., Clifton, P. M., Wittert, G. A., Tomlinson, L., Galletly, C., Luscombe, N. D., & Norman, R. J. (2004). Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition. *The Journal of Clinical Endocrinology and Metabolism*, 89(7), 3337–3344. <https://doi.org/10.1210/jc.2003-031583>
- Pavlidou, E., Papadopoulou, S. K., Seroglou, K., & Giaginis, C. (2023). Revised Harris–Benedict Equation: New Human Resting Metabolic Rate Equation. *Metabolites*, 13(2), 189. <https://doi.org/10.3390/metabo13020189>
- Pedersen, T. L. (2023). *Patchwork: The Composer of Plots*.
- Persson, S., Elenis, E., Turkmen, S., Kramer, M. S., Yong, E.-L., & Poromaa, I. S. (2021). Higher risk of type 2 diabetes in women with hyperandrogenic polycystic ovary syndrome. *Fertility and Sterility*, 116(3), 862–871. <https://doi.org/10.1016/j.fertnstert.2021.04.018>
- Pesonen, E., Nurkkala, M., Niemelä, M., Morin-Papunen, L., Tapanainen, J. S., Jämsä, T., Korpelainen, R., Ollila, M.-M., & Piltonen, T. T. (2023). Polycystic ovary syndrome is associated with weight-loss attempts and perception of overweight independent of BMI: A population-based cohort study. *Obesity (Silver Spring, Md.)*, 31(4), 1108–1120. <https://doi.org/10.1002/oby.23681>
- Rodriguez-Sanchez, F., cre, cph, Jackson, C. P., Hutchins, S. D., & Clawson, J. M. (2023). *Grateful: Facilitate Citation of R Packages*.
- Salari, N., Nankali, A., Ghanbari, A., Jafarpour, S., Ghasemi, H., Dokaneheifard, S., & Mohammadi, M. (2024). Global prevalence of polycystic ovary syndrome in women worldwide: A comprehensive systematic review and meta-analysis. *Archives of Gynecology and Obstetrics*, 310(3), 1303–1314. <https://doi.org/10.1007/s00404-024-07607-x>
- Segal, K. R., & Dunaif, A. (1990). Resting metabolic rate and postprandial thermogenesis in polycystic ovarian syndrome. *International Journal of Obesity*, 14(7), 559–567.
- Steele, J., Fisher, Smith, Schoenfeld, Yang, & Nakagawa, S. (2023). Meta-analysis of variation in sport and exercise science: Examples of application within resistance training research. *Journal of Sports Sciences*, 41(17), 1617–1634. <https://doi.org/10.1080/02640414.2023.2286748>
- Stefanaki, K., Karagiannakis, D. S., Peppas, M., Vryonidou, A., Kalantaridou, S., Goulis, D.

- G., Psaltopoulou, T., & Paschou, S. A. (2024). Food Cravings and Obesity in Women with Polycystic Ovary Syndrome: Pathophysiological and Therapeutic Considerations. *Nutrients*, 16(7), 1049. <https://doi.org/10.3390/nu16071049>
- Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., & Joham, A. E. (2023). Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. *The Journal of Clinical Endocrinology and Metabolism*, 108(10), 2447–2469. <https://doi.org/10.1210/clinem/dgad463>
- Ushey, K., cre, Wickham, H., Software, P., & PBC. (2023). *Renv: Project Environments*.
- Velasquez, J. R. (2011). The Use of Ammonia Inhalants Among Athletes. *Strength & Conditioning Journal*, 33(2), 33. <https://doi.org/10.1519/SSC.0b013e3181fd5c9b>
- Viechtbauer, W. (2023). *Metafor: Meta-Analysis Package for R*.
- Wan, X., Wang, W., Liu, J., & Tong, T. (2014). Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Medical Research Methodology*, 14(1), 135. <https://doi.org/10.1186/1471-2288-14-135>
- Wickham, H., Chang, W., Henry, L., Pedersen, T. L., Takahashi, K., Wilke, C., Woo, K., Yutani, H., Dunnington, D., Posit, & PBC. (2023). *Ggplot2: Create Elegant Data Visualisations Using the Grammar of Graphics*.